Navigation Links
Severe Gum Disease Triples Heart Disease Risk

RICHMOND, Virginia - Researchers at the Virginia Commonwealth University have found that increased levels of plasma lipoprotein in patients with advanced periodontitis may be responsible for increasing the risk of heart disease in these patients. //

Periodontitis is the inflammation of the supporting tissue that surrounds the teeth. Previous studies have already linked its presence with a host of diseases including diabetes and cardiovascular disease. The current study suggests that checking on the plasma lipoprotein profile in patients with severe periodontitis might be life-saving as appropriate therapy can be instituted. Lead author Rik van Antwerpen, Ph.D., an assistant professor of biochemistry at VCU said that the study was a pointer towards the risk of these patients to develop heart disease in the future, “Previous research has shown that people who have predominantly small-dense LDL in their blood are at a three- to six-fold increased risk of heart disease and stroke. A person may have predominantly small-dense LDL without having alarmingly high blood levels of cholesterol. Therefore, unhealthy levels of small-dense LDL are not always detected in regular cholesterol tests” The current study was conducted on a small scale and involved 12 patients with advanced periodontal disease and 12 without any disease, who acted as controls.

Another factor that could link up to heart disease is the presence of platelet activating factor acetylhydrolase (PAF-AH), which is an enzyme that is associated with small-dense LDL. This enzyme could be responsible for lowering the atherogenic effects of LDL. In severe periodontitis this association between LDL-associated PAF-AH activity is lowered and thus may speed up cardiovascular disease. The study appears in the December issue of the Journal of Lipid Research and was supported by grants from the National Institutes of Health.

CONTACT: Sathya Achia-Abraham University News Services Phone:
'"/>




Page: 1 2

Related medicine news :

1. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
2. Severe stress weakens immunity
3. Severe Acute respiratory Syndrome (SARS)
4. WHO Travel Advice to prevent spread of "Severe Acute Respiratory Syndrome (SARS)
5. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
6. Severe sleep apnea can cause liver problems
7. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
8. Strong Magnetic Stimulation Can Help Treating Severe Depression
9. Patients Suffering From Severe Mental Diseases Are At Risk Of Being Crime Victims
10. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
11. Poor Glycaemic Control In Hispanics With Diabetes Causes Severe Depression
Post Your Comments:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 1CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 1Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 5Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3